Rate My Professor Ranjit Manchanda

Professor Ranjit Manchanda is Professor of Gynaecological Oncology at the Wolfson Institute of Population Health, Faculty of Medicine and Dentistry, Queen Mary University of London, and Consultant Gynaecological Oncologist at Barts Health NHS Trust, where he leads the Women’s Precision Prevention Service. He is Co-Lead of the Cancer Prevention Unit and the Cancer Screening, Prevention and Epidemiology Unit, and holds an Honorary Professorship in the Department of Health Services Research at the London School of Hygiene and Tropical Medicine. Originally trained at the All India Institute of Medical Sciences in Delhi, India, he holds MD, MRCOG qualifications and completed a PhD in gynaecological oncology at University College London, followed by an NIHR Academic Clinical Lectureship Fellowship and subspecialty training in gynaecological oncology at University College London Hospital and Barts Hospital. His career trajectory includes Locum Consultant Gynaecological Oncologist and Honorary Senior Lecturer at Barts Health and University College London (2014-2015), Clinical Senior Lecturer at Barts Cancer Institute, Queen Mary University of London (2015), and appointment to his current professorship in September 2019.

Professor Manchanda’s research focuses on targeted precision prevention in gynaecological oncology, encompassing population-based genetic testing, mainstreaming of genetic testing, precision medicine approaches for risk prediction and stratification, targeted screening, surgical cancer prevention, familial cancer management, and associated health economics. As Chief Investigator, he directs pivotal studies including PROTECTOR (Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal), PROTECT-C (Population based Germline testing for Early detection and Cancer Prevention), DETECT-2, PROMISE Feasibility study, SIGNPOST, RRESDO, and GCaPPS trial; he is Co-PI on UKCOGS and SURAKSHA, and has contributed to ovarian cancer screening trials UKCTOCS, UKFOCSS, and ALDO. His impact extends to leadership as Chair of the UK National Cancer Research Institute Gynaecological Cancer Early Diagnosis Working Group, NIHR North Thames Clinical Research Network Specialty Research Lead for Gynaecological Cancer, Topic Advisor for NICE Ovarian Cancer: identifying and managing familial and genetic risk guideline, NHS Innovation Accelerator Alumnus, and former President of the European Network of Young Gynaecological Oncologists. Notable honors include the NIHR ACL Fellowship, William Blair Bell Memorial Lecture (2018), and Distinguished Infosys Chair in Oncology at the All India Institute of Medical Sciences (2022). He has published widely, with key works such as 'Cost-effectiveness of population based BRCA testing with short-term and lifetime clinical outcomes: a health economic evaluation' (2017) and 'Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer Following Implementation of the U.K. Familial Ovarian Cancer Screening Study (UKFOCSS)' (2017).